An event-driven, phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficiency, safety, immunogenicity, & lot-to-lot consistency of Bbv152, a whole-varion inactivated Sars-Cov-2 vaccine in adults more than 18 to years of age | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

An event-driven, phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficiency, safety, immunogenicity, & lot-to-lot consistency of Bbv152, a whole-varion inactivated Sars-Cov-2 vaccine in adults more than 18 to years of age

Implementing Organization

ICMR-National Institute of Research In Tribal Health Madhya Pradesh

Principal Investigator

Mr. M. Shameem Professor ICMR-National Institute of Research In Tribal Health Madhya Pradesh

Related Research

Quick Information

Area of Research

Medical Sciences

Focus Area

Task Force (TF)

Start Year

2020

End Year

2021

Duration

17

Sanction Amount

₹ 15.56 Cr

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

00

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…